Objective: Our purpose was to examine the effects of daily servings of butter, no-trans-fat margarine and plant sterol margarine, within recommended amounts, on plasma lipids, apolipoproteins (Apos), biomarkers of inflammation and endothelial dysfunction, and on the transfer of lipids to HDL particles in free-living subjects with the metabolic syndrome. Methods: This was a randomized, single-blind study where 53 metabolic syndrome subjects (62% women, mean age 54 years) received isocaloric servings of butter, no-trans-fat margarine or plant sterol margarine in addition to their usual diets for 5 weeks. The main outcome measures were plasma lipids, Apo, inflammatory and endothelial dysfunction markers (CRP, IL-6, CD40L or E-selectin), small dense LDL cholesterol concentrations and in vitro radioactive lipid transfer from cholesterol-rich emulsions to HDL. Difference among groups was evaluated by analysis of variance. Results: There was a significant reduction in Apo-B (À10.4 %, P ¼ 0.043) and in the Apo-B/Apo-A-1 ratio (À11.1%, P ¼ 0.034) with plant sterol margarine. No changes in plasma lipids were noticed with butter and no-trans-fat margarine. Transfer rates of lipids to HDL were reduced in the no-trans-fat margarine group: triglycerides À42.0%, (Po0.001 vs butter and sterol margarine) and free cholesterol À16.2% (P ¼ 0.006 vs sterol margarine). No significant effects were noted on the concentrations of inflammatory and endothelial dysfunction markers among the groups. Conclusions: In free-living subjects with the metabolic syndrome consumption of plant sterol and no-trans-fat margarines within recommended amounts reduced, respectively, Apo-B concentrations and the ability of HDL to accept lipids.
Introduction
Population studies have documented that increased intakes of dietary saturated fat and cholesterol (butter, dairy products and meats) and decreased intakes of polyunsaturated fat have been associated with an increased risk of cardiovascular disease (CVD) (Stamler, 1979; McGee et al., 1984; Kromhout et al., 1984 Kromhout et al., , 1985 . When vegetable oil and vegetable oil margarines have replaced butter and dairy products in intervention studies a significant reduction in heart disease risk has been noted (Leren, 1966; Dayton et al., 1968; Turpeinen, 1979) . Dietary fat has an essential role in modulating immune and inflammatory responses, with both quantity and quality of fats having been shown to affect these processes (Han et al., 2002) .The type and degree of fatty acid unsaturation has also been shown to affect immune and inflammatory responses (Calder, 1998) .
There has been a great interest in providing spreads that are rich in essential fatty acids to the general population. These include margarines devoid of trans fats that contain either plant stanols or plant sterols. It has been known for some time that the cholesterol-lowering effects of plant sterols are due to the inhibition of cholesterol absorption (Trautwein et al., 2003) . In addition, daily intakes of 2 g per day of plant sterols reduce cholesterol absorption by about 30-40% (Katan et al., 2003; Normén et al., 2004) . Similar effects were noted when plant stanols were used as shown in a recent meta-analysis (Demonty et al., 2009) . These investigators also noted that greater reductions in lowdensity lipoprotein (LDL) cholesterol were observed when the baseline levels of LDL cholesterol were higher. We have previously documented that, when margarine is compared with butter at 20% of calories under controlled circumstances, LDL cholesterol levels are 10-12% lower after consumption of soybean oil or semi-liquid margarine than after consumption of butter. Furthermore this difference was minimized when subjects consumed high-trans-fat margarines (Lichtenstein et al., 1999) .
Overweight people with elevated waist circumference frequently have a cluster of abnormalities, which includes increased fasting glucose, hyperinsulinemia, elevated blood pressure, low levels of high-density lipoprotein (HDL) cholesterol, high plasma triglyceride and increased levels of inflammatory markers in their blood (Dandona et al., 2005) . A commonly used term for the clustering of abnormalities associated with being overweight is the metabolic syndrome (NCEP/ III, ATP 2002; Eckel et al., 2005) . Persons with the metabolic syndrome are at essentially twice the risk for CVD when compared with those without the syndrome. It further raises the risk for type-2 diabetes by about five-fold (Grundy, 2008) .
HDL particles are constantly being remodeled by bidirectional lipid transfers, which are essential for the role of the lipoprotein in cholesterol esterification and in reverse cholesterol transport, whereby cholesterol from peripheral tissues is transferred to the liver and excreted in bile (Wang and Briggs, 2004) . Because the lipid transfer process is a determinant of HDL composition and thereby for the adhesion of proteins to the lipoprotein surface, it is possible that other atheroprotective functions of the lipoprotein may also be affected by this process. We have developed a method that evaluates the ability of the lipoprotein to simultaneously receive its main constituent lipid classes, namely phospholipids, free cholesterol, esterified cholesterol and triacylglycerols, from a cholesterol-rich nanoemulsion. This approach has allowed us to determine changes in the transference rates of lipids to HDL in heart transplant , HIV-positive (Daminelli et al., 2008) subjects and after statin treatment .
There is very limited information about the addition of margarine spreads in the free-living state, important for the simulation of the real life, in patients with the metabolic syndrome (Plat et al., 2009) . Our aims in this study were to compare the effects of butter, no-trans-fat margarine and plant sterol margarine within recommended amounts (NCEP/ATP III, 2002) on plasma lipids, lipoproteins, apolipoproteins (Apos), inflammatory and endothelial dysfunction markers, and lipid transfer rates from emulsions to HDL in metabolic syndrome subjects.
Methods

Study subjects
This protocol was approved by the Ethics in Research Committee (CAPPESQ) of the University of Sao Paulo Medical School Hospital, Brazil, and all subjects signed informed consent. For enrollment into this study we screened over 150 subjects for the presence of the metabolic syndrome, according to the NCEP ATP III criteria (NCEP/ATP III, 2002), from July 2005 to November 2008. However, all male subjects were required to have a waist circumference 4102 cm and female subjects a waist size circumference 488 cm, in addition to any two of the following criteria:
(1) presence of arterial hypertension either as treated high blood pressure or having a blood pressure 4130/85 mm Hg; (2) an HDL cholesterol level o40 mg/dl in men and o50 mg/ dl in women; (3) a fasting triglyceride value 4150 mg/dl and (4) a fasting glucose level 4100 mg/dl. The use of lipidlowering and glucose-lowering drugs, as well as alcohol consumption, were the exclusion criteria for this study. Blood pressure medications had to be in a stable dose during the study duration.
After screening 150 subjects, 75 subjects were found to be eligible and were randomized equally into one of three groups. Of these, 53 subjects (62.3% women) completed the protocol. A total of 18, 16 and 19 subjects completed the study, respectively, in the butter group, the no-trans-fat margarine group and the plant sterol margarine group. The clinical characteristics of the studied subjects are shown in Table 1 . Fasting serum lipid and glucose levels for the 53 subjects completing the study at baseline were as follows: total cholesterol 207±36 mg/dl, LDL cholesterol 128 ± 37 mg/dl, HDL cholesterol 48 ± 17 mg/dl, triglycerides 180 ± 95 mg/dl and glucose 99 ± 10 mg/dl. No differences were noted between the subjects in each diet group at baseline with regard to clinical and biochemical parameters. There were 22 subjects who were excluded or were dropouts during the study, with the major reason being self-reported noncompliance, namely, not consuming the spreads. Additional reasons for exclusion included subjects not returning for the final visit or starting cholesterol-lowering medications during the study. All study subjects were provided with one of the three products for periods of 35 days.
Spreads provided to study subjects All subjects enrolled in the study were asked to continue their regular diet in the free-living state and to continue their regular activity level. Spreads were dispensed in a singleblinded manner in portion packs for daily use. Subjects assigned to the butter group (Laticinios Aviação, Sao Sebastiao do Paraiso, Brazil) were given 18 g/day of butter containing 8.4 g of saturated fat. Subjects randomized respectively to no-trans-fat and plant sterol margarines (Unilever Corporation, Sao Paulo, Brazil) were given 36 g/day and 30 g per day (2.4 g of plant sterols). These amounts were chosen to provide approximately equal amounts of total lipids (12.6-12.86 g/day) and calories (96-115.5 per day), and also to provide adequate amounts of plant sterols for the plant sterol margarine. The fatty acid composition of each of the products is provided in Table 2 and was determined in the Lipid Laboratory of the University of Sao Paulo Pharmaceutical Science School by gas chromatographic (GC 17A Shimadzu/ Class GC 10, Kyoto, Japan) separation of fatty acid methyl esters. Analyses were made on 100 m Â 0.25 mm fused silica capillary SP-2560 columns using method 996.06 of the Association of Official Analytical Chemistry (Association of Official Analytical Chemists (AOAC), 2002).
Study protocol
Subjects were allocated into the groups according to randomization and came to the clinic at baseline and after 5 weeks for a fasting blood draw. During the study they were 102.7 ± 8.5 104.9 ± 9.2 100.5 ± 9.4 102.6 ± 6.6 Hypertension 20 10 (55.6%) 8 (50%) 12 (63.2%) Smokers 3 (5.6%) 2 (11.1%) 1 (6.2%) 0 (0) Values are means ± s.d.; categorical variables: n (%). monitored biweekly by telephone calls to assure compliance. Only those subjects who were consuming the products (minimum consumption at least 30 days supply of spread product provided and less than 3 days of consecutive nonconsumption of the spread) were included in the study and were completers. In addition, all subjects were required to provide daily food records for three selected days, at the start of the study, in the middle of the study and at the end of the study, for a total of three daily food records. Information about their diets is provided in Table 3 .
Laboratory measurements
For blood drawing, all subjects were asked to fast overnight, for at least 12 h, and had approximately 30 cc of blood drawn in EDTA tubes for isolation of plasma and in red top tubes for isolation of serum. Serum total cholesterol, triglyceride, direct LDL cholesterol and direct HDL cholesterol were measured by automated enzymatic methods using kits obtained from Roche Diagnostics (Sao Paulo, Brazil). Small dense LDL cholesterol was measured in the Lipid Metabolism Laboratory at Tufts University using automated standardized enzymatic analysis using kits provided by Denka-Senken Corporation (Tokyo, Japan), which just measures the cholesterol in small dense LDL cholesterol as previously described (Ai et al., 2008) . Non-HDL cholesterol was calculated by subtracting HDL cholesterol from total cholesterol, and the ratio of LDL to HDL was also calculated.
Plasma Apo-A-I and Apo-B were measured by automated standardized immunoassays using kits obtained from Roche Diagnostics, and the Apo-B/Apo-A-I ratio was calculated. The transfer rates of cholesteryl ester, phospholipid, free cholesterol and triglyceride from cholesterol-rich emulsions to HDL was determined in the Lipid Metabolism Laboratory of the Heart Institute (InCor) as previously described (Daminelli et al., 2008; Giribela et al., 2009; Lo Prete et al., 2009; Puk et al., 2009) . Lipid nanoemulsions were prepared from a lipid mixture of 40 mg cholesteryl oleate, 20 mg egg phosphatidylcholine, 1 mg triolein and 0.5 mg cholesterol purchased from the Sigma Chemical Company (St Louis, MO, USA). Lipid emulsification was performed by prolonged ultrasonic irradiation in an aqueous media as previously described (Maranhão et al., 1993) . Trace amounts of cholesteryl (7(n)-3H) oleate and glycerol tri (9, 10 (n)-3H) oleate or (1-14C) cholesterol and L-3-phosphatidylcholine, 1-stearoyl-2-(1-14C) arachidonyl (Amersham, Buckinghamshire, UK) were added to the initial solution. To assay the lipid transfer rate to HDL, plasma with EDTA in a volume of 200 ml was incubated with 50 ml of the nanoemulsion labeled either with Values are means ± s.d. 1 ¼ baseline, 2 ¼ in the middle, 3 ¼ final; no significant differences were found within the groups in time.
containing no precipitation reagents (Daminelli et al., 2008; Lo Prete et al., 2009 ). Intra-assay precision studies included 10 replicates of samples. Inter-assay precision was calculated on the basis of three assays of 10 replicates, run on three different days. Intra-assay coefficient of variation was 0.83% for phospholipids, 0.56% for free cholesterol, 1.49% for esterified cholesterol and 0.51% for triglycerides, indicating consistent reproducibility. Inter-assay showed no difference between samples for transfer of all lipids (phospholipids ¼ 0.78; free cholesterol ¼ 0.59; esterified cholesterol ¼ 1.32; triglycerides ¼ 0.58).
In addition, markers of inflammation and endothelial dysfunction were measured at the Clinical Emergencies Laboratory of the University of Sao Paulo Medical School Hospital, at baseline and after 5 weeks of therapy; these included immunoassays for C-reactive protein (CRP), interleukin-6 (IL-6), CD 40 ligand (CD40L) and E-selectin. E-selectin and CD40L ELISA obtained from R&D Systems (Minneapolis, MN, USA) were used. For IL-6, ELISA from BD Biosciences Pharmingen (San Jose, CA, USA) was used, and for CRP an immunoassay from Dade-Behring (Newark, DE, USA) Siemens was used.
Statistical analyses
Baseline characteristics of studied groups were compared by one-way analysis of variance. Inter and intra-group differences between the baseline and experimental diets were analyzed by repeated-measures analysis of variance. When data normality was rejected the non parametric test of Kruskall-Wallis was used. The data are expressed as median (minimumÀmaximum) and median of % of variation (minimumÀmaximum variation), and significance levels are provided as P-values, with Po0.05 being considered statistically significant. Statistical analyses were performed using SPSS 15.0 for windows.
Results
The composition of the spreads used in this study are shown in Table 2 . The amount of saturated fatty acid in butter was equal to 5.0% of a 1500-calorie diet, and this value was within the recommendation of up to 7% of total calories as saturated fat (NCEP/ATP III, 2002). Polyunsaturated fatty acids predominated in the plant sterol margarine and in the no-trans-fat margarine . It is recommended that polyunsaturated fatty acid consumption is less than 10% of the total caloric value (NCEP/ATP III, 2002), and these margarines supplied 4.2% of the calories in these fats for a diet of 1500 calories. In the plant sterol margarine there was also an addition of plant sterols (2.4 g in the offered portion, in agreement with the manufacturer).
No significant changes in blood pressure, body weight (data not shown) or on food consumption (Table 3) were noted over the 5-week course of the study in any of the three study groups. There was an increasing variation in the consumption of dietary cholesterol, especially the group consuming no-trans margarine; however this variation was not statistically significant. This variation may have been a random effect, as the subjects remained in a free-living state during the entire study.
The effect of the spreads on plasma lipids andApos, inflammatory and endothelial dysfunction markers and lipid transfers to HDL are shown in Tables 4-6, respectively. There were no differences among the groups regarding baseline parameters. There was a significant reduction in Apo-B levels (À10.5%, P ¼ 0.043) and in the ratio of Apo-B/ Apo-A-I (À11%, P ¼ 0.034) with plant sterol margarines vs baseline. Changes in Apo-B were also significant in relation to the other groups.
No differences were noted with regard to changes in total cholesterol, HDL cholesterol, small dense LDL and non-HDL cholesterol, triglyceride or LDL/HDL ratios. However, there was a decrease of 11.4% in LDL cholesterol in the plant sterol margarine group (P ¼ 0.051). Table 5 shows the evolution of inflammatory and endothelial dysfunction markers on the different groups; no significant changes in CRP, E-selectin, IL-6 or CD-40L were noted for any spread group.
Data on lipid transfer rates between labeled lipids in nanoemulsions to HDL are shown in Table 6 . Of great interest in this investigation was the fact that the no-trans-fat margarine induced significant reductions in the transfer rate of labeled lipids from nanoemulsions to HDL in relation to baseline and the other groups: triglyceride À43.3% (Po0.001 vs butter and sterol margarine) and free cholesterol À16.4% (P ¼ 0.006 vs sterol margarine). No significant changes in lipid transfer rates were observed for the butter or plant sterol margarine groups.
Discussion
This study showed that in contrast to butter, no-trans-fat and plant sterol margarines when consumed within recommended portions can modify Apos and HDL metabolism in metabolic syndrome subjects on their usual diets. There were reductions in Apo B levels and changes in HDL metabolism respectively for sterol and trans-free margarines.
Beneficial effects on cardiovascular risk have been noted when saturated fats were replaced by polyunsaturated fats (Schaefer, 2002) . In addition a recent meta-analysis (Demonty et al., 2009) supports the concept that approximately 2 g of plant sterols in margarine reduces LDL cholesterol by about 10%. In our study virtually the same effect was observed. When 30 g of plant sterol margarine (2.4 g of plant sterols) were provided daily to 19 subjects with metabolic syndrome, mean LDL cholesterol, Apo-B levels and Apo-B/Apo-A-I ratio were decreased by 11.4, 10.4 and 11.1%, respectively, as compared with baseline values. No such changes were observed in the butter or no-trans-fat margarine groups. Recently Plat et al. (2009) have found in nine metabolic syndrome patients that a plant stanol yogurt reduced Apo B levels by 5%. The ratio of Apo-B/Apo-A-I is an important risk marker for CVD (McQueen et al., 2008) . Previously, Madsen et al. (2007) had observed an only 3.4% decrease in this ratio after plant sterol margarine consumption was compared with a placebo in hypercholesterolemic individuals for a period of 4 weeks. Our results document even greater benefits in patients with the metabolic syndrome.
In our study no significant changes were found in the cholesterol concentration carried in the small dense LDL sub-fraction despite reductions in Apo-B concentrations with the sterol margarine spread. Our data suggest that in freeliving subjects where only diet counseling was performed all three spreads did not change the concentrations of small dense LDL cholesterol. The neutral results found with both margarines are in accord with the data from the Framingham Offspring study (Campos et al., 1992) where no association was found between small dense LDL concentration and polyunsaturated fat consumption. However, our results contrast with the findings of studies where diet portfolio was tested (Gigleux et al., 2007; Lamarche et al., 2004) and where significant changes were found in the cholesterol carried in the small dense LDL fraction. This might be explained by the fact that the portfolio diet contained not only plant sterols but was also restricted in saturated fat and rich in soluble fibers. As a consequence Apo-B and LDL cholesterol levels were reduced at a greater intensity, approximately 30 and 25% vs 11 and 10%, respectively, in our study. Therefore the changes in Apo-B and LDL cholesterol found in the free-living subjects in our study might not result in significant reductions in the cholesterol carried in small dense LDL particles. Conversely it is important to emphasize that in the study of Lamarche et al. (2004) cholesterol was reduced in all subclasses of LDL particles. One possibility is that cholesterol reduction occurred preferentially in bigger size LDL particles in our population. Finally, methodological differences could also explain the distinct findings: LDL particles were measured by gradient gel electrophoresis and their cholesterol content was extrapolated to the small dense LDL sub-fraction in the diet portfolio studies (Gigleux et al., 2007; Lamarche et al., 2004) whereas small dense LDL cholesterol was directly measured after precipitation in our study.
Limited data are available on the effect of diet on CRP and other inflammatory and endothelial dysfunction markers in metabolic syndrome patients (Lichtenstein et al., 2003; Plat et al., 2009) . In our study no significant changes in CRP, IL-6, CD40L or E-selectin were found with either butter or the two types of trans-free margarines in comparison with baseline. Lichtenstein et al. (2003) also observed that levels of CRP were not affected by changing dietary fatty acid intakes (soybean oil, semi-liquid margarine, soft margarine, shortening, traditional stick margarine or butter). Plat et al. (2009) also found no changes in CRP, ICAM (intercellular adhesion Apo-B (mg/dl)* molecular), VCAM (vascular cell adhesion molecular) and E-selectin in a small number of metabolic syndrome subjects that received sitostanol yogurt (Plat et al., 2009) . Our results suggest that consumption of butter, no-trans-fat margarine or plant sterol margarine, within the usual recommendations does not modify inflammatory and endothelial dysfunction markers. Whether larger fatty acid amounts or a longer study period are necessary to show the affect of these spreads remains to be determined. HDL particles exert their anti-atherosclerotic effects by either facilitating reverse cholesterol transport or by their anti-inflammatory properties among other mechanisms (Wang and Briggs, 2004) . The transfer of lipids from peripheral tissues and from plasma lipoproteins is a dynamic process mediated by cellular transporters from the ATP-binding cassette family (Lewis and Rader, 2005) or by plasma proteins like cholesterol ester transfer protein, phospholipid transfer protein and lecithin cholesterol acyl transferase. The assay used in this study allows evaluation of the in vitro the ability of HDL particles to receive lipids from other lipoproteins. Changes in the transfer rates of lipids to HDL were detected by this method in heart transplantation patients and in post-menopausal women (Giribela et al., 2009; Puk et al., 2009) . The most novel feature of our study was the significant decrease in lipid transfer rates for free cholesterol and triglycerides from lipid emulsions to HDL. For all of these transfers, the triglyceride transfer rate was reduced the most by the no-trans-fat margarine. This effect was not observed in the plant sterol margarine group or butter group. It is known that triglyceride-rich, cholesterolpoor HDL is more likely to be found in patients with low HDL and premature CHD, as compared with that in controls (Asztalos and Schaefer, 2003; Kontush and Chapman, 2008; Rye et al., 2009) . In addition, with fat feeding there is a significant increase in triglyceride-rich lipoproteins as well as the triglyceride content of HDL (Cohn et al., 1988) . Furthermore, triglyceride-rich enriched HDL has been shown to be less anti-inflammatory than normal HDL in terms of its ability to suppress endothelial cell production of the adhesion molecules ICAM-1 and VCAM, as well as being less efficient as a donor of cholesterol to liver cells through scavenger receptor-B1 for efficient reverse cholesterol transport (Kontush and Chapman, 2008; Masson et al., 2009; Miyazaki et al., 2009 ). This study was not aimed at determining the physiological mechanisms regulating the transfer of lipids to HDL; however, experimental evidence suggests that enrichment of HDL in free cholesterol is associated with increment in the transference of triglycerides to these particles (Morton, 1988) . Possibly the reduction in free cholesterol transfer to HDL by non-trans margarine could have influenced the transference of triglycerides to HDL. However, further studies are necessary to clarify these mechanisms. Also, it remains to be determined whether plant sterol-induced reduction in Apo-B-containing lipoproteins has counterbalanced the effects of the polyunsaturated fatty acids of the no-trans margarine on lipid transfers. Limitations of this study are related to the fact that it was not performed in a controlled environment when all food ingested by study subjects was controlled. However, the food records showed a constant food quality consumption pattern in the studied subjects. We cannot rule out that larger amounts of dietary fats could have influenced the studied parameters. However, the main objective was to test spread consumption under real-life conditions and within recommended fatty acid amounts.
In conclusion, in this study plant sterol margarine reduced Apo-B and Apo-B/Apo-A-l ratios and no-trans-fat margarine altered the functionality of HDL particles. Furthermore, butter and no-trans-fat margarine consumption, within recommended amounts, did not unfavorably change plasma lipids and inflammatory markers in free-living metabolic syndrome subjects.
